loading page

Counterbalancing the Hydroxychloroquine Induced QT Prolongation: COVID 19 and Beyond
  • +2
  • Ertan Yetkin,
  • Didem Tascioglu,
  • Sirin Yurtlu Temel,
  • Bilal CUGLAN,
  • Kenan Yalta
Ertan Yetkin
Istinye University
Author Profile
Didem Tascioglu
Istinye Universitesi
Author Profile
Sirin Yurtlu Temel
Istinye University
Author Profile
Bilal CUGLAN
Beykent University
Author Profile
Kenan Yalta
Trakya Universitesi
Author Profile

Abstract

Those patients with progressive QT prolongation or QT interval exceeding >500 ms may complete the COVID 19 treatment protocol containing HCQ and/or AZM without serious arrhythmias and torsades de pointes by the adding the mexiletine or lidocaine as an adjunctive drug in those patients. Counterbalancing the QT prolongation by mexiletine in association with would further decrease the labor and stress of healthcare providers during the continuing COVID 19 pandemic. Although it is a big dilemma how the therapeutic or prophylactic use of HCQ will end up, the pathophysiologic effects of HCQ on QT interval and counterbalancing by antiarryhthmic drugs mexiletine and lidocaine is out of the current discussion of COVID 19 pandemics. Counter balancing effect of mexiletine and lidocaine on QT interval in patients receiving HCQ would be helpful in patients with not only COVID 19 but also in malaria and rheumatologic disease as well.